BioSig Technologies Inc SEC Filings

BSGM NASDAQ

Welcome to our dedicated page for BioSig Technologies SEC filings (Ticker: BSGM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading BioSig’s filings can feel like scrubbing through hundreds of pages of electrophysiology jargon just to confirm one clinical-trial milestone. Stock Titan removes that friction by turning every BioSig Technologies SEC document into plain language insights, updated the moment they reach EDGAR.

Our AI engine pinpoints what investors ask for most—including R&D spend buried in a BioSig Technologies quarterly earnings report 10-Q filing, FDA feedback disclosed in an 8-K material events explained note, and dilution risks outlined in a BioSig Technologies annual report 10-K simplified. You’ll also get real-time alerts on BioSig Technologies Form 4 insider transactions real-time so you can track when executives trade shares around pivotal PURE EP announcements.

Skip the slog of cross-referencing forms. Stock Titan links each question to the right filing type:

Form 4: BioSig Technologies insider trading Form 4 transactions & BioSig Technologies executive stock transactions Form 4
10-Q: Quarterly revenue trends and BioSig Technologies earnings report filing analysis
10-K: Cash runway, IP status, and risk factors—BioSig Technologies SEC filings explained simply
DEF 14A: BioSig Technologies proxy statement executive compensation

Whether you’re understanding BioSig Technologies SEC documents with AI for the first time or benchmarking peer med-tech disclosures, our platform delivers AI-powered summaries, keyword search across every exhibit, and expert commentary you can trust. Make faster, evidence-based decisions without decoding electrophysiology vocabulary on your own.

07/09/2025 09:22 AM

Filing

[8-K] BioSig Technologies, Inc. Reports Material Event

Rhea-AI Summary

BioSig Technologies, Inc. (NASDAQ: BSGM) filed an 8-K announcing two capital‐raising arrangements with YA II PN, Ltd. that could provide up to $1.1 billion in fresh liquidity.

1. $100 million Senior Secured Convertible Debentures

$75 million first tranche and $25 million second tranche; purchase price 96% of face value (4% original-issue discount).
24-month maturity, 4.0% cash or PIK interest (rising to 18% on default); 10% prepayment premium.
Conversion price = lower of (i) 125% prior-day VWAP (subject to one downward reset) or (ii) 97% of the lowest VWAP in the three trading days before conversion, with a floor at 20% of the Nasdaq closing price.
Shareholder approval required for issuances above the 19.99% Exchange Cap; investor ownership capped at 4.99%.
Obligations secured by a first-priority lien on nearly all assets of BioSig and subsidiaries (excluding $50 million earmarked for working capital, including gold tokenisation initiatives); standard events of default apply.

2. $1 billion Standby Equity Purchase Agreement (SEPA)

36-month commitment; sales priced at 97% of the lowest VWAP over the three days following each Advance Notice.
No SEPA draws until debentures are fully repaid or converted unless the investor waives the restriction.
Ownership limited to 4.99% and subject to the same 19.99% Exchange Cap unless shareholder approval or volume-weighted price test (≥ $9.414) is met.
1% commitment fee, payable in cash or shares.

All securities are issued in private placements under Section 4(a)(2) and will be registered for resale pursuant to a forthcoming registration statement. Directors, officers and key shareholders have agreed to 180-day lock-ups.

Investor Take-away: The facilities materially strengthen near-term liquidity and fund strategic projects, but they introduce significant dilution risk and pledge substantially all company assets. Shareholder approval hurdles and market-price-dependent conversion features add execution and pricing uncertainty.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of BioSig Technologies (BSGM)?

The current stock price of BioSig Technologies (BSGM) is $5.23 as of July 11, 2025.

What is the market cap of BioSig Technologies (BSGM)?

The market cap of BioSig Technologies (BSGM) is approximately 284.1M.

What is the PURE EP Platform?

The PURE EP Platform is an FDA-cleared non-invasive Class II device developed by BioSig Technologies. It uses advanced digital signal processing to deliver precise real-time visualization of intracardiac signals, aiding in cardiac ablation procedures.

How does BioSig’s technology improve electrophysiology procedures?

BioSig’s technology enhances electrophysiology by digitizing and amplifying intracardiac signals, thereby reducing noise and providing higher resolution imaging. This allows physicians to accurately identify arrhythmogenic regions and execute targeted ablation treatments.

What makes BioSig Technologies different from other medical device companies?

BioSig distinguishes itself by integrating sophisticated hardware and software to achieve unprecedented signal clarity. Its focus on real-time digital signal processing in electrophysiology, coupled with ongoing AI and robotics exploration, sets it apart in the competitive cardiac care market.

Who are the primary customers of BioSig Technologies?

The primary customers include hospitals, cardiac ablation centers, and electrophysiology laboratories. These institutions benefit from the enhanced signal visualization during diagnostic and interventional procedures in cardiac care.

What role does digital signal processing play in BioSig’s products?

Digital signal processing is central to BioSig’s approach. It enables the immediate amplification, digitization, and processing of intracardiac signals to ensure accurate, noise-reduced visualization, which is critical for effective cardiac electrophysiology procedures.

How does BioSig ensure the clinical efficacy of its devices?

BioSig ensures clinical efficacy through rigorous FDA regulatory clearances, extensive collaboration with leading clinicians, and a robust validation process during product development. This commitment to high standards underpins the safety and performance of its devices.

What strategic initiatives support BioSig’s market position?

BioSig’s market position is supported by strategic vendor negotiations, active industry partnerships, and potential asset acquisitions. These initiatives help optimize operational efficiency and keep its technology platform at the forefront of the electrophysiology space.

Can BioSig’s technology integrate with existing electrophysiology systems?

Yes, the PURE EP Platform is designed to complement existing electrophysiology systems. Its advanced processing capabilities can integrate with current lab configurations, enhancing the overall diagnostic and treatment workflow in cardiac care.